Promising Outlook for Tenaya Therapeutics: Buy Rating Justified by Innovative Gene Therapy Potential
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed for Tenaya Therapeutics Amid Promising TN-201 Data and Financial Stability
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Tenaya Therapeutics Analyst Ratings
CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Cuts Target Price to $6
Promising Developments in Tenaya Therapeutics' TN-201 Program Justify Buy Rating
TD Cowen Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Tenaya Therapeutics Price Target Cut to $6.00/Share From $18.00 by Canaccord Genuity
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Tenaya Therapeutics Analyst Ratings
Promising Clinical Data and Financial Stability Support Buy Rating for Tenaya Therapeutics Despite Price Target Reduction
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Cuts Target Price to $5
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Cuts Target Price to $3
Morgan Stanley Maintains Overweight on Tenaya Therapeutics, Lowers Price Target to $5
Chardan Adjusts Price Target on Tenaya Therapeutics to $9 From $18, Keeps Buy Rating
Morgan Stanley Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Cuts Target Price to $5